Bosentan for pulmonary hypertension and other pulmonary diseases: Emerging evidence

Research output: Contribution to journalArticle

Abstract

Endothelin-1 is a potent vasoconstrictor and mitogen that is primarily synthesized and released from vascular endothelial cells. Bosentan is a dual endothelin-receptor antagonist that initially received approval for treatment of WHO group I pulmonary arterial hypertension (PAH) for patients in functional classes III and IV. Analysis of a study conducted in functional class II patients (Endothelin Antagonist Trial in Mildly Symptomatic PAH Patients (EARLY) trial) suggest its efficacy for these less symptomatic patients. In addition, bosentan has demonstrated efficacy in patients with congenital heart disease and Eisenmengers syndrome with right to left shunting and in HIV-related PAH. Studies of bosentan in inoperable or residual chronic thromboembolic pulmonary hypertension suggest possible efficacy. Bosentan appears promising in patients with idiopathic pulmonary fibrosis who do not have pulmonary hypertension. Combinations of bosentan with other PAH therapies such as iloprost and slidenafil may have incremental benefit over monotherapy.

Original languageEnglish (US)
Pages (from-to)459-468
Number of pages10
JournalFuture Cardiology
Volume4
Issue number5
DOIs
StatePublished - Sep 2008

Fingerprint

Pulmonary Hypertension
Lung Diseases
Eisenmenger Complex
Iloprost
Idiopathic Pulmonary Fibrosis
Vasoconstrictor Agents
Endothelin-1
Mitogens
bosentan
Heart Diseases
Endothelial Cells
HIV
Therapeutics

Keywords

  • Bosentan
  • Endothelin
  • Endothelin-receptor antagonist
  • Pulmonary hypertension
  • Scleroderma

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Bosentan for pulmonary hypertension and other pulmonary diseases : Emerging evidence. / Frantz, Robert.

In: Future Cardiology, Vol. 4, No. 5, 09.2008, p. 459-468.

Research output: Contribution to journalArticle

@article{9626cbd72ae249938f645e05e1573fcd,
title = "Bosentan for pulmonary hypertension and other pulmonary diseases: Emerging evidence",
abstract = "Endothelin-1 is a potent vasoconstrictor and mitogen that is primarily synthesized and released from vascular endothelial cells. Bosentan is a dual endothelin-receptor antagonist that initially received approval for treatment of WHO group I pulmonary arterial hypertension (PAH) for patients in functional classes III and IV. Analysis of a study conducted in functional class II patients (Endothelin Antagonist Trial in Mildly Symptomatic PAH Patients (EARLY) trial) suggest its efficacy for these less symptomatic patients. In addition, bosentan has demonstrated efficacy in patients with congenital heart disease and Eisenmengers syndrome with right to left shunting and in HIV-related PAH. Studies of bosentan in inoperable or residual chronic thromboembolic pulmonary hypertension suggest possible efficacy. Bosentan appears promising in patients with idiopathic pulmonary fibrosis who do not have pulmonary hypertension. Combinations of bosentan with other PAH therapies such as iloprost and slidenafil may have incremental benefit over monotherapy.",
keywords = "Bosentan, Endothelin, Endothelin-receptor antagonist, Pulmonary hypertension, Scleroderma",
author = "Robert Frantz",
year = "2008",
month = "9",
doi = "10.2217/14796678.4.5.459",
language = "English (US)",
volume = "4",
pages = "459--468",
journal = "Future Cardiology",
issn = "1479-6678",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Bosentan for pulmonary hypertension and other pulmonary diseases

T2 - Emerging evidence

AU - Frantz, Robert

PY - 2008/9

Y1 - 2008/9

N2 - Endothelin-1 is a potent vasoconstrictor and mitogen that is primarily synthesized and released from vascular endothelial cells. Bosentan is a dual endothelin-receptor antagonist that initially received approval for treatment of WHO group I pulmonary arterial hypertension (PAH) for patients in functional classes III and IV. Analysis of a study conducted in functional class II patients (Endothelin Antagonist Trial in Mildly Symptomatic PAH Patients (EARLY) trial) suggest its efficacy for these less symptomatic patients. In addition, bosentan has demonstrated efficacy in patients with congenital heart disease and Eisenmengers syndrome with right to left shunting and in HIV-related PAH. Studies of bosentan in inoperable or residual chronic thromboembolic pulmonary hypertension suggest possible efficacy. Bosentan appears promising in patients with idiopathic pulmonary fibrosis who do not have pulmonary hypertension. Combinations of bosentan with other PAH therapies such as iloprost and slidenafil may have incremental benefit over monotherapy.

AB - Endothelin-1 is a potent vasoconstrictor and mitogen that is primarily synthesized and released from vascular endothelial cells. Bosentan is a dual endothelin-receptor antagonist that initially received approval for treatment of WHO group I pulmonary arterial hypertension (PAH) for patients in functional classes III and IV. Analysis of a study conducted in functional class II patients (Endothelin Antagonist Trial in Mildly Symptomatic PAH Patients (EARLY) trial) suggest its efficacy for these less symptomatic patients. In addition, bosentan has demonstrated efficacy in patients with congenital heart disease and Eisenmengers syndrome with right to left shunting and in HIV-related PAH. Studies of bosentan in inoperable or residual chronic thromboembolic pulmonary hypertension suggest possible efficacy. Bosentan appears promising in patients with idiopathic pulmonary fibrosis who do not have pulmonary hypertension. Combinations of bosentan with other PAH therapies such as iloprost and slidenafil may have incremental benefit over monotherapy.

KW - Bosentan

KW - Endothelin

KW - Endothelin-receptor antagonist

KW - Pulmonary hypertension

KW - Scleroderma

UR - http://www.scopus.com/inward/record.url?scp=55249083557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55249083557&partnerID=8YFLogxK

U2 - 10.2217/14796678.4.5.459

DO - 10.2217/14796678.4.5.459

M3 - Article

C2 - 19804340

AN - SCOPUS:55249083557

VL - 4

SP - 459

EP - 468

JO - Future Cardiology

JF - Future Cardiology

SN - 1479-6678

IS - 5

ER -